drugset / Trial / NCT01723813
Peptide Vaccinations Plus GM-CT-01 in Melanoma
Phase 1/2
Terminated
6 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the intravenous and/or GM-CT-01 administration can correct Tumor Infiltrating Lymphocytes (TIL) anergy and induce a more efficient and long-lasting anti-tumoral immune response following peptide vaccination.
Timeline
- Start
- 2012-04
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAVANAT | Other / unclassified | 100 ug | Intravenous |
| Subject | DAVANAT | Other / unclassified | 280 mg/m2 | Intravenous |
| Subject | MAGE-3.A1 | Peptide | 300 ug | Intramuscular |
| Subject | NA17.A2 | Peptide | 300 ug | Intramuscular |